Condition
Peripheral T Cells Lymphoma (PTCL)
Total Trials
4
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
P 1 (3)
P 2 (1)
Trial Status
Recruiting3
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07018752Phase 1RecruitingPrimary
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas
NCT07372352Phase 2RecruitingPrimary
Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCL
NCT07139353Phase 1Not Yet RecruitingPrimary
Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
NCT06495723Phase 1RecruitingPrimary
Polyspecific Antibodies in Lymphoproliferative T-cell Disorders
Showing all 4 trials